Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedmethotrexate
Educational only, not medical advice. OncoForge makes no claim that Methotrexate treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
Neuro-oncology · Oct 2025 · phase 3 randomized controlled trial
Methotrexateembryonal brain tumorsmedulloblastomaGroup 3 medulloblastomaSHH medulloblastomaembryonal tumor with multilayered rosettespineoblastoma
This phase 3 randomized trial tested adding high-dose methotrexate to induction chemotherapy in children ≤36 months with high-risk embryonal brain tumors. Overall complete response rates were similar between arms, but in medulloblastoma patients methotrexate was associated with higher CR (63% vs 30%) and improved 5-year event-free survival in Group 3 medulloblastoma (70% vs 33.3%). No benefit was seen for embryonal tumor with multilayered rosettes or pineoblastoma.
Reported effects: eligible patients 77, n=77 · patients evaluated for response 59, n=59 · +8 more
Of 77 eligible patients, 59 with detectable disease were evaluated for response and 28 (47.5%) achieved CR; 15/30 (50%) treated with methotrexate compared to 13/29 (45%) without methotrexate (P = 0.35).
For medulloblastoma (MB), CR was 12/19 (63%) with methotrexate compared to 6/20 (30%) without methotrexate (P = 0.039).
All SHH subtype MB (n = 11) were survivors (molecular characterization retrospective).
Five-year event-free survival (EFS) for Group 3 MB was 70% (90% CI: 39.6-87.2) with methotrexate versus 33.3% (90% CI: 15.0-52.9) without (P = 0.037).
In other embryonal tumors, CR was 3/11 (27%) with methotrexate compared to 7/9 (78%) without (P = 0.99).
No benefit observed for Embryonal Tumor with Multilayered Rosettes (n = 14; EFS 20.0% [90% CI: 1.8-52.5] with methotrexate versus 33.3% [90% CI: 10.8-58.1] without, P = 0.58) or pineoblastoma (n = 9; EFS 16.7% [90% CI: 1.6-46.1] with methotrexate versus 0% without, P = 0.52).
Limitations: Relatively small overall sample size (77 eligible) with smaller numbers in histologic/molecular subgroups; Molecular characterization was conducted retrospectively; Some subgroup analyses involve very small n (e.g., Group 3 MB: 10 vs 15; SHH MB n=11); Tests of significance were one-sided (as stated); Confidence intervals reported are 90% rather than the more conventional 95%.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Methotrexate's evidence base, and anything that's been retracted.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Embryonal brain tumors●Human trial / meta-analysis◆Mixed results1 human
Includes human trial or meta-analysis evidence.
Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies
Embryonal tumor with multilayered rosettes●Human trial / meta-analysis◆Mixed results1 human
Includes human trial or meta-analysis evidence.
Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies
Group 3 medulloblastoma●Human trial / meta-analysis◆Mixed results1 human
Includes human trial or meta-analysis evidence.
Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies
Medulloblastoma●Human trial / meta-analysis◆Mixed results1 human
Includes human trial or meta-analysis evidence.
Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies
Pineoblastoma●Human trial / meta-analysis◆Mixed results1 human
Includes human trial or meta-analysis evidence.
Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies
SHH medulloblastoma●Human trial / meta-analysis◆Mixed results1 human
Includes human trial or meta-analysis evidence.
Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies
These are doses as studied or reported, never a recommendation. The right amount of Methotrexate depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.